ivermectin in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Gonzalez (IVER), 2020 0.83 [0.23; 3.02]
Kirti, 2021 0.12 [0.01; 2.36]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
0.61 [0.20 ; 1.88 ] Gonzalez (IVER), 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 337 moderate not evaluable clinical deteriorationdetailed results RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
0.53 [0.15 ; 1.95 ] RIVET-COV (Mohan) (12mg and 24mg), 2021 1 0% 125 NA not evaluable clinical improvement (7-day)detailed results Kirti, 2021 0.90 [0.77; 1.06]
0.90 [0.77 ; 1.06 ] Kirti, 2021 1 0% 112 NA not evaluable death or ventilationdetailed results Gonzalez (IVER), 2020 0.89 [0.30; 2.64]
0.89 [0.30 ; 2.64 ] Gonzalez (IVER), 2020 1 0% 73 NA not evaluable hospital dischargedetailed results Gonzalez (IVER), 2020 0.71 [0.15; 3.40]
Kirti, 2021 1.20 [0.73; 1.98]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
1.25 [0.80 ; 1.95 ] Gonzalez (IVER), 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 310 moderate not evaluable mechanical ventilationdetailed results Kirti, 2021 0.20 [0.00; 8.69]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
0.32 [0.02 ; 4.80 ] Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 264 moderate not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.93 [0.78 ; 1.10 ] Chaccour, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 138 low not evaluable viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
4.10 [1.12 ; 14.99 ] Ahmed, 2020 1 0% 72 NA not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
4.10 [1.12 ; 14.99 ] Ahmed, 2020 1 0% 72 NA not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Kirti, 2021 0.80 [0.43; 1.50]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
0.92 [0.78 ; 1.08 ] Chaccour, 2020, Kirti, 2021, RIVET-COV (Mohan) (12mg and 24mg), 2021 3 0% 250 low not evaluable ICU admissiondetailed results Kirti, 2021 0.90 [0.30; 2.70]
0.90 [0.30 ; 2.70 ] Kirti, 2021 1 0% 112 NA not evaluable serious adverse eventsdetailed results RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
0.52 [0.01 ; 26.47 ] RIVET-COV (Mohan) (12mg and 24mg), 2021 1 0% 152 NA not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
1.17 [0.49 ; 2.78 ] Chaccour, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021 2 0% 176 moderate not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-08 01:51 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 684,886
- roots T: 290
